Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Behind the Genes cover art

Behind the Genes

Behind the Genes

Written by: Genomics England
Listen for free

About this listen

At Genomics England, our vision is a world where everyone benefits from genomic healthcare.

From the latest research to the lived experiences of those affected by rare conditions and cancer, Behind the Genes brings you closer to the people behind the science.

Each month, we release a deep-dive episode, alongside our Genomics 101 series - short explainers designed to make complex terms in genetics and genomics easier to understand.

Copyright 2021 All rights reserved.
Biological Sciences Science Social Sciences
Episodes
  • What is pharmacogenomics?
    Nov 11 2026
    In this explainer episode, Dr Jude Hayward, GP and Principal Clinician for Primary Care at Genomics England, explains what we mean by pharmacogenomics. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you’ve got any questions, or have any other topics you’d like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Florence: [00:00:00] What do we mean by pharmacogenomics? My name is Florence Cornish, and today I'm here with Jude Hayward, who is principal clinician for primary care here at Genomics England, and she is going to be telling us much more about the topic. So, Jude, thanks so much for being here. It's great to have you. Jude: Thank you, Florence, and thank you for the invitation, delighted to be here. I'm Dr. Jude Hayward. I am principal clinician for primary care, and that's my role within Genomics England. I am a GP, and I work half-time as a GP, and I also work as a GPER, a GP with an extended role in clinical genetics. I have other roles nationally, working as primary care lead for the Genomics Education Programme, and also representing genomic medicine for the Royal College of General Practitioners. And really, this is through my interest in implementing genomic medicine into primary care, supporting my primary care colleagues, and this most recently has led me to have an interest in pharmacogenomics. Florence: [00:01:00] And so, Jude, when we say the word pharmacogenomics, we're actually saying a combination of two words, right? We're saying pharmacology, combined with genomics. And so, it might be helpful if we could start by explaining each of those on their own first. Could you talk through what we mean by the word genomics? Jude: Yes, absolutely. And genomics will be familiar to the listeners of the podcast. The genome is our full set of DNA. Part of the genome is genes, and each of these genes acts as an instruction, so the genome acts as an instruction manual for everything about us. Genomics is the study of this genome, and genomic medicine is how the genome can impact their health. Florence: Mm-hmm. Jude: Moving on to pharmacology, this is the study of how medicines and chemicals interact with and affect the body and how we process and handle medications within our bodies. Florence: And so if we combine both of these together, genomics and pharmacology, we get this pharmacogenomics, which is presumably kind of a mashup of the two, right? Looking at how a person's genes can affect their response to medicines. [00:02:00] Would you say that that's accurate? Can you tell us a little bit more about it? Jude: Yes. I think that's a great description, Florence. So yes, essentially, pharmacogenomics is a study of how a person's genome interacts with the way that they respond to medication. So, it is a type of personalized medication. We all carry the same genes. We all carry the genes which affect the way that we respond to medications, and we carry changes or variants in these genes which affect the way that we handle certain medications. [00:02:30] But these only become relevant if we are prescribed a medication which is going to interact and form what's called a gene-drug pair. Florence: Yeah. So, tell me a little bit more about that. Why do medicines work differently for different people? Why do we see this happening? Jude: Well, there's a variety of different reasons for this. There's multiple factors which affect how an individual may respond or react to a certain medication. So pharmacogenomics is one, and even there, there are multiple different variants that may occur. And so there are multiple different ways in which our genomic information, our genomes, can affect how we respond. [00:03:00] But in addition to that, there's all sorts of other things as well. So, what we eat affects how we might react to medication. Other genes, maybe other conditions that we have will affect how we react to a medication, other medications we're taking will affect how we react to a medication and there's all sorts of other environmental factors as well. Florence: Do you have any real-world examples that we know of, of genes that people have that might affect their response to specific medications? Jude: [00:03:30] Yes. The one that I'm going to talk about is one called CYP2C19. Now, that's how it's said, but it's actually spelt C-Y-P-2-C-1-9, which is just essentially a reference number for the gene CYP2C19. This is one that people may have heard of because it's been in the news over the last couple of years. So, we know that if people have a stroke or a mini stroke, that at the moment the usual practice is to offer them a prescription of a medication that can thin their blood down, and one of the common ones is one called clopidogrel. Florence: [00:04:00] Mm-hmm. Jude: And this has been prescribed for people for many, many years, and it ...
    Show More Show Less
    9 mins
  • Can we change the rules of medicine?
    Oct 27 2026
    Advances in genomics are making it possible to develop treatments for individual patients with rare genetic conditions. But how can we get these treatments to the people who need them when traditional medicine development is designed for much larger groups of patients? In this episode, our guests explore the challenges of developing and approving personalised medicines, and how researchers, regulators and patient advocates can work together to bridge the gap between scientific advances and patient access. Our host Sharon Jones is joined by: Dr Dan O’Connor, Executive Director Regulatory, Association of the British Pharmaceutical Industry (ABPI) Julia Vitarello, founder and CEO of Mila’s Miracles Foundation Professor Rich Scott, CEO of Genomics England If you enjoyed today’s conversation, please like and share wherever you listen to your podcasts. “The technology's there, and it's now just saying, "Well, actually, can the system catch up?" And that's really the clear message I think we have to do. We've got to somehow align with the fast-evolving opportunities that new technology will offer us, and ensure that patients get the medicines they really need.” You can download the transcript, or read it below. Sharon Jones: Hello and welcome to Behind the Genes, the podcast that brings you the stories, research, and innovations shaping the future of genomic healthcare. For decades, medicines have been developed and tested for large groups of people, but advances in genomics are opening up new possibilities, including treatments tailored to an individual's genetic condition. So how do you adapt a system built for thousands of patients when there may only be a handful of people in the world who could benefit from a particular treatment? [00:00:30] Today, we're exploring how researchers, regulators, and patient advocates are working together to rethink the way new medicines are developed and approved. I'm Sharon Jones, and joining me today are Dr. Dan O'Connor, executive director regulatory, the Association of the British Pharmaceutical Industry; Julia Vitarello, Mila's mum, and founder and CEO of Mila's Miracles Foundation; and Professor Rich Scott , CEO of Genomics England. [00:01:00] By the way, you're going to hear a powerful story from Julia about her daughter, Mila. Sharon Jones: If you want to hear it in full, the episode is called Mila to Millions, and you can find it in the episode description. Julia, I'd like to start with you. You've shared your story with us on the podcast before, but for listeners who may not know it, can you briefly explain what's brought you here today? Julia: Yeah. Thank you, Sharon. [00:01:30] My daughter, Mila was born completely typical and was running around and hiking and singing and playing like other children until she was six when she was diagnosed with 100% fatal rare genetic disease called Batten Disease. And I was told in just one minute that my daughter would lose all of her abilities and die in the next few years. As you can imagine, my life in many ways ended in that moment. All my hopes and dreams of my daughter just were erased in one minute to the next. [00:02:00] But I saw her fighting. I saw her lose her vision. I saw her lose her ability to eat by mouth and have a G-tube put in and start having up to 30 seizures a day, and she was still smiling and laughing. And I just said, "You know, if she can fight, I can fight." And I started a foundation and raced against time alongside Boston Children's Hospital and Dr. Timothy Yu. And in a very miraculous, Herculean effort to save my daughter's life, we moved to Boston one year later, and my daughter started receiving a medicine called Milasen that was named after her. And the reason it was named after her is because while her condition was already very small with only 25 children in the world at the time, she was the only one that shared that specific mutation and the only one that could benefit from that medicine. And at that time, my daughter then became the first person in the world to receive a medicine for one person. It stopped her disease for the first year, um, but it wasn't in time for her. When she was 10, she died. [00:03:00] And the reason that I am still here is because my daughter showed what was possible, that we now have the incredible science and technology to be able to find the root cause of disease, often a single mutation, and design a medicine, even if it's unique to one person. And so I have been on a mission here to try to figure out how to help the millions of other families like mine in need. Sharon Jones: Julia, thank you for sharing that. I mean, you know, it's a difficult listen and, you know, thank you for kind of going through what you've been through for, you know, numerous times on this podcast and sharing with listeners how, how hard that was. Milia's story is incredibly powerful, and what really comes through is how much you fought to find answers. ...
    Show More Show Less
    30 mins
  • How do we keep medicines safe and working properly?
    Oct 14 2026
    In this explainer episode, Rachel Brucoli, Deputy Director at the Medicines and Healthcare products Regulatory Agency, explains how we make sure that medicines stay safe and work properly. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you’ve got any questions, or have any other topics you’d like us to explain, let us know on podcast@genomicsengland.co.uk. Read more about the MHRA via their website. You can download the transcript or read it below. Florence: How do we make sure that our medicines stay safe and work properly? My name is Florence Cornish, and today I'm joined by Rachel Brucoli, who is a Deputy Director at the Healthcare products Regulatory Agency, also known as the MHRA. And Rachel is here to tell us much more about the topic Well, firstly, Rachel, thank you so much for joining us today. It's great to have you on. Rachel: Thank you. Nice to be here. Florence: The first question I wanted to ask you is quite a big question and I guess the crux of this entire episode really. Um, but how do we ensure that medicines are safe and work properly before they get to patients? Rachel: Yeah, it's an important question, isn't it? So in the UK, medicines are regulated by the Medicines and Healthcare Products Regulatory Agency or MHRA for short. And that's to ensure they, they are safe, they work correctly in a specified disease, and they're made to a high standard before they reach the public. In line with the relevant law, which is the Human Medicines Regulation, before a medicine is allowed to be placed on the market in the UK, the MHRA reviews safety information from clinical trials to ensure that the medicine does not cause unexpected or unacceptable effects. We also review efficacy data from clinical trials to make sure that the medicine works in the disease or condition and in the patient population that the manufacturer claims it does. Um, another important aspect that's reviewed is how the medicine's manufactured. It's very important that the medicine is made consistently and that every batch meets agreed specifications. Florence: And so you used that word regulation a few times. When we say that medicines are regulated, how do we do that? What does that process actually look like? Rachel: Yeah. So different countries have different laws that govern how medicines are regulated. And as I mentioned before, in the UK, the relevant legislation is the Human Medicines Regulations. In addition, different countries have different pathways or procedures for licensing of medicines, but it's worth noting that the types of data looked at by regulators is similar, and we've got harmonised standards in, in many respects. In the UK, different types of application can be submitted depending on the type of medicine under review. So for example, the data submitted for a brand-new medicine containing a new active substance that hasn't been approved in the UK would differ from that submitted for a generic medicine. The licensing process is triggered when a marketing authorisation application is submitted to the MHRA by a pharmaceutical company or a biotech company. And for new medicines, this application contains a significant amount of data that's been generated over, um, a large number of years. Florence: Mm-hmm. Can you tell us a little bit more about that? What types of information are submitted to you in this process? Rachel: Yes. So there's three main types of information that, that we receive. Um, the first is quality data, and that provides evidence that the medicinal product can be made safely, reliably, and to a high standard. It describes what the medicine's made of, how it's made, and provides evidence that the medicine can be produced consistently. The second body of data contains the results of the non-clinical studies, and there they characterize the pharmacology, and the safety profiles of the active ingredient of the medicine. And the third section of the application is the results and analyses of all the clinical studies conducted with the proposed medicine. These clinical studies will have been conducted in phases, and they're designed to determine the optimal dose of the medicine needed to treat the specific disease and to provide evidence that the medicine works, or as we would say, is efficacious, and that's usually compared to placebo. So, what's being measured in clinical studies are clinical endpoints, and they are specific outcomes or events that are measured to determine if a new treatment works. So, I guess giving an example of that is a cancer medicine, um, where a relevant endpoint that could be measured might include overall, an increase in overall survival or a reduction in tumour size. Additionally, some other important, outcomes could be patient-reported, such as effects on quality of life. So these clinical data will be analysed using appropriate statistical methods, and then ...
    Show More Show Less
    12 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet